CTOR vs NKTR

Analysts rate Citius Oncology, Inc.

(CTOR) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Nektar Therapeutics (NKTR) delivered a total return of -69.

4%, compared to -92. 0% for Citius Oncology, Inc. (CTOR). Over 10 years, the gap is even starker: NKTR returned -57. 6% versus CTOR's -92. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Nektar Therapeutics (NKTR) is the lower-risk stock at 1.

85β versus Citius Oncology, Inc. 's 1. 86β — meaning CTOR is approximately 1% more volatile than NKTR relative to the S&P 500. On balance sheet safety, Citius Oncology, Inc. (CTOR) carries a lower debt/equity ratio of 8% versus 95% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Nektar Therapeutics grew EPS -12.

1% year-over-year, compared to -13. 3% for Citius Oncology, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Citius Oncology, Inc.

(CTOR) is the more profitable company, earning 0. 0% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CTOR leads at 0. 0% versus -253. 7% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 86. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Nektar Therapeutics (NKTR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

Citius Oncology, Inc. (CTOR) carries a higher beta of 1. 86 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NKTR: -57. 6%, CTOR: -92. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.